{"id":"autologous-hematopoietic-stem-cell-transplant","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Infection"},{"rate":"5-15%","effect":"Bleeding"},{"rate":"5-15%","effect":"Nausea and vomiting"},{"rate":"5-15%","effect":"Fatigue"},{"rate":"5-15%","effect":"Pain"},{"rate":"1-5%","effect":"Hypersensitivity reactions"},{"rate":"1-5%","effect":"Organ toxicity"}]},"_chembl":{"chemblId":"CHEMBL5315099","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This process allows the body to regenerate its own healthy blood cells, replacing those damaged by cancer treatment or disease. The treated stem cells then help the body recover from the effects of chemotherapy or radiation therapy.","oneSentence":"Autologous Hematopoietic Stem Cell Transplant involves collecting a patient's stem cells, treating them to eliminate cancer cells, and then reinfusing them to help the body produce healthy blood cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:53.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory Hodgkin lymphoma"},{"name":"Relapsed or refractory non-Hodgkin lymphoma"},{"name":"Multiple myeloma"},{"name":"Acute myeloid leukemia"},{"name":"Breast cancer"},{"name":"Lung cancer"},{"name":"Melanoma"},{"name":"Multiple sclerosis"},{"name":"Sickle cell disease"},{"name":"Severe autoimmune disorders"}]},"trialDetails":[{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT05071222","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-19","conditions":"Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency","enrollment":7},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT06915246","phase":"PHASE2","title":"A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma","status":"RECRUITING","sponsor":"VIVUS LLC","startDate":"2025-03-12","conditions":"Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":49},{"nctId":"NCT04975698","phase":"PHASE2","title":"HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2021-10-25","conditions":"HIV Associated Lymphoma","enrollment":12},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT04680468","phase":"PHASE2","title":"Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-06-02","conditions":"Myeloma","enrollment":41},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":"Mantle Cell Lymphoma","enrollment":689},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Non-Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT07485647","phase":"PHASE2","title":"Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing","status":"NOT_YET_RECRUITING","sponsor":"Eden Biltibo","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05405387","phase":"PHASE2","title":"Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-05-03","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":120},{"nctId":"NCT01011920","phase":"PHASE2","title":"Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-11","conditions":"Central Nervous System Lymphoma","enrollment":227},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT05397496","phase":"PHASE1","title":"Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-10-03","conditions":"B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)","enrollment":61},{"nctId":"NCT03901963","phase":"PHASE3","title":"A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-04-26","conditions":"Multiple Myeloma","enrollment":200},{"nctId":"NCT05827016","phase":"PHASE3","title":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-06-22","conditions":"Multiple Myeloma","enrollment":1216},{"nctId":"NCT05552222","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-25","conditions":"Multiple Myeloma","enrollment":1590},{"nctId":"NCT05357482","phase":"PHASE1, PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":"Sickle Cell Anemia, Beta Thalassemia","enrollment":40},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT03477539","phase":"PHASE2","title":"Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-04-09","conditions":"Plasma Cell Myeloma","enrollment":49},{"nctId":"NCT07458854","phase":"NA","title":"Exercise in Patients Undergoing Autologous Stem Cell Transplantation: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2014-10-14","conditions":"Hematologic Malignacy, Autologous Hematopoietic Stem Cell Transplantation","enrollment":15},{"nctId":"NCT05540340","phase":"PHASE1","title":"A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-09","conditions":"Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell","enrollment":39},{"nctId":"NCT00026312","phase":"PHASE3","title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10-26","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":1449},{"nctId":"NCT05434689","phase":"PHASE1, PHASE2","title":"COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-01-18","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT03964792","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-11-12","conditions":"Sickle Cell Disease","enrollment":6},{"nctId":"NCT07451652","phase":"PHASE2","title":"Low Dose Epcoritamab Plus GemOx in R/R DLBCL","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2026-02","conditions":"Relapsed/Refractory Diffuse Large B Cell Lymphoma","enrollment":10},{"nctId":"NCT04802356","phase":"PHASE2","title":"Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2021-04-07","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05091372","phase":"PHASE2","title":"Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-12-01","conditions":"Myeloma Multiple","enrollment":94},{"nctId":"NCT07432867","phase":"PHASE1, PHASE2","title":"Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-02-25","conditions":"Sickle Cell Disease","enrollment":15},{"nctId":"NCT05681195","phase":"PHASE2","title":"Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2024-04-25","conditions":"Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer","enrollment":15},{"nctId":"NCT01555892","phase":"PHASE1","title":"Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2013-01-14","conditions":"Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease","enrollment":136},{"nctId":"NCT05271630","phase":"","title":"Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-04-20","conditions":"Multiple Myeloma","enrollment":69},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT07441291","phase":"PHASE3","title":"CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-11-30","conditions":"B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive","enrollment":70},{"nctId":"NCT03158896","phase":"PHASE1","title":"Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-07-09","conditions":"Acute Graft Versus Host Disease","enrollment":24},{"nctId":"NCT05432635","phase":"PHASE1","title":"Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-01","conditions":"B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma","enrollment":15},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT06679829","phase":"PHASE2","title":"A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-11-06","conditions":"Multiple Myeloma","enrollment":215},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging","enrollment":40},{"nctId":"NCT05199311","phase":"PHASE1, PHASE2","title":"Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2022-05-13","conditions":"Multiple Myeloma","enrollment":66},{"nctId":"NCT03909412","phase":"PHASE1","title":"Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2019-10-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT07413809","phase":"PHASE3","title":"Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2025-10-31","conditions":"Multiple Myeloma","enrollment":92},{"nctId":"NCT06851767","phase":"PHASE1, PHASE2","title":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-09","conditions":"X-linked Severe Combined Immunodeficiency, X-SCID, XSCID","enrollment":18},{"nctId":"NCT05393804","phase":"PHASE2","title":"A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-05-20","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT03538899","phase":"PHASE1, PHASE2","title":"Autologous Gene Therapy for Artemis-Deficient SCID","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2018-05-31","conditions":"Severe Combined Immunodeficiency","enrollment":24},{"nctId":"NCT07409454","phase":"PHASE2","title":"MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT05561751","phase":"PHASE2","title":"Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","status":"COMPLETED","sponsor":"GPCR Therapeutics, Inc.","startDate":"2023-02-13","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT02523976","phase":"PHASE2","title":"Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2015-08-01","conditions":"Acute,Leukemia, Lymphoid","enrollment":30},{"nctId":"NCT04390971","phase":"NA","title":"Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-02-10","conditions":"Transfusion Dependent Beta-Thalassaemia","enrollment":3},{"nctId":"NCT03622775","phase":"PHASE2","title":"Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-11","conditions":"Recurrent Plasma Cell Myeloma","enrollment":13},{"nctId":"NCT06685536","phase":"","title":"A Long-term Follow-up Study in Participants Who Received CS-101","status":"ENROLLING_BY_INVITATION","sponsor":"CorrectSequence Therapeutics Co., Ltd","startDate":"2025-01-18","conditions":"Beta-Thalassemia","enrollment":5},{"nctId":"NCT07392970","phase":"PHASE2","title":"Motixafortide for MRD Sensitization in AML","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Acute Myeloid Leukemia, Measurable Residual Disease","enrollment":10},{"nctId":"NCT06153797","phase":"NA","title":"A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-01-01","conditions":"Hematologic Malignancy, Caregiver","enrollment":80},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT04876248","phase":"PHASE2","title":"Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-08-19","conditions":"Plasma Cell Myeloma","enrollment":4},{"nctId":"NCT07387848","phase":"PHASE2","title":"Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"American University of Beirut Medical Center","startDate":"2026-04-15","conditions":"Diffuse Large B Cell Lymphoma Refractory","enrollment":40},{"nctId":"NCT06647979","phase":"PHASE1","title":"Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies","status":"RECRUITING","sponsor":"Daniel Bauer","startDate":"2025-12-01","conditions":"Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Beta-Thalassemia","enrollment":10},{"nctId":"NCT05180097","phase":"PHASE2","title":"Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2022-11-01","conditions":"Hodgkin Lymphoma","enrollment":84},{"nctId":"NCT06216158","phase":"PHASE3","title":"Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2024-04-05","conditions":"Multiple Myeloma","enrollment":411},{"nctId":"NCT01511562","phase":"PHASE2","title":"Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2012-09","conditions":"Lymphoma","enrollment":113},{"nctId":"NCT04262167","phase":"PHASE1","title":"Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2020-10-22","conditions":"Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease","enrollment":24},{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04150042","phase":"PHASE1","title":"SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells","status":"RECRUITING","sponsor":"General Oncology, Inc.","startDate":"2021-01-13","conditions":"Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation","enrollment":24},{"nctId":"NCT07365306","phase":"PHASE2","title":"Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-12-30","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma","enrollment":43},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT07362810","phase":"PHASE2","title":"G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-01","conditions":"Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB), Hematopoetic Stem Cell Transplantation, Hemato-oncologic Patients","enrollment":224},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT06974786","phase":"PHASE2","title":"Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2025-08-08","conditions":"Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)","enrollment":100},{"nctId":"NCT05706766","phase":"NA","title":"Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-06-29","conditions":"Multiple Myeloma, Stem Cell Transplant Complications","enrollment":30},{"nctId":"NCT06197672","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2024-03-19","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT01208662","phase":"PHASE3","title":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paul Richardson, MD","startDate":"2010-09","conditions":"Multiple Myeloma","enrollment":729},{"nctId":"NCT07353840","phase":"","title":"T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-01-20","conditions":"Peripheral T Cell Lymphoma","enrollment":160},{"nctId":"NCT07346820","phase":"","title":"VDJ-recombination of the B-cell Receptor Following Hematopoietic Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Umeå University","startDate":"2026-02-01","conditions":"Stem Cell Transplantation, Hematopoietic, V(D)J Recombination, Receptors, Antigen, B-Cel","enrollment":65},{"nctId":"NCT03246529","phase":"PHASE3","title":"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioLineRx, Ltd.","startDate":"2018-03-23","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT03897361","phase":"PHASE1, PHASE2","title":"Stem Cell Gene Therapy for Cystinosis","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2019-07-08","conditions":"Lysosomal Storage Diseases, Cystinosis","enrollment":6},{"nctId":"NCT02441686","phase":"PHASE2","title":"Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT05852717","phase":"PHASE2","title":"Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Dipenkumar Modi","startDate":"2023-10-31","conditions":"Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer","enrollment":32},{"nctId":"NCT04443907","phase":"PHASE1","title":"Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-08-25","conditions":"Sickle Cell Disease","enrollment":4},{"nctId":"NCT02619682","phase":"PHASE2","title":"Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2015-12-30","conditions":"Plasma Cell Myeloma, Transplant-Related Carcinoma","enrollment":30},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT04745221","phase":"NA","title":"Efficacy and Safety of Auto-FMT in Preventing aGVHD","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-03-01","conditions":"Graft Versus Host Disease, Acute","enrollment":100},{"nctId":"NCT04331119","phase":"PHASE2","title":"Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-07-23","conditions":"T-Cell Lymphoma","enrollment":17},{"nctId":"NCT05642884","phase":"NA","title":"Prehabilitation Feasibility Among Older Adults Undergoing Transplantation","status":"RECRUITING","sponsor":"Noha Mohamed Sharafeldin","startDate":"2023-07-10","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT05130827","phase":"PHASE2","title":"Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-21","conditions":"Multiple Myeloma","enrollment":17},{"nctId":"NCT07253129","phase":"","title":"Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-12-31","conditions":"Peripheral T Cell Lymphoma","enrollment":88},{"nctId":"NCT04653246","phase":"PHASE2","title":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacob Laubach, MD","startDate":"2021-07-13","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant","enrollment":52},{"nctId":"NCT06149403","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orchard Therapeutics","startDate":"2023-12-11","conditions":"MPS-IH (Hurler Syndrome)","enrollment":41},{"nctId":"NCT05317416","phase":"PHASE3","title":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-25","conditions":"Multiple Myeloma","enrollment":811},{"nctId":"NCT07209501","phase":"NA","title":"Evaluating the Feasibility and Acceptability of Inhalation Aromatherapy for Patients Undergoing Autologous Haematopoietic Stem Cell Transplant (HSCT)","status":"ENROLLING_BY_INVITATION","sponsor":"Singapore General Hospital","startDate":"2025-05-15","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":30},{"nctId":"NCT01850888","phase":"NA","title":"MIBG for Refractory Neuroblastoma and Pheochromocytoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-12","conditions":"Relapsed Neuroblastoma, Metastatic Pheochromocytoma","enrollment":15},{"nctId":"NCT03317899","phase":"PHASE2","title":"Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-10-12","conditions":"Non-Hodgkin's Lymphoma, Plasma Cell Myeloma","enrollment":77},{"nctId":"NCT02247843","phase":"PHASE1, PHASE2","title":"Stem Cell Gene Therapy for Sickle Cell Disease","status":"COMPLETED","sponsor":"Donald B. Kohn, M.D.","startDate":"2014-12","conditions":"Sickle Cell Disease","enrollment":4},{"nctId":"NCT06514508","phase":"PHASE3","title":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2025-12-01","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT00692939","phase":"PHASE1, PHASE2","title":"Autologous Stem Cell Transplantation for Crohn's Disease","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2012-06-26","conditions":"Crohn's Disease","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":324,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HSCT"],"phase":"phase_2","status":"active","brandName":"Autologous Hematopoietic Stem Cell Transplant","genericName":"Autologous Hematopoietic Stem Cell Transplant","companyName":"Gary A Levy, O. Ont. MD. FRCP AGAF","companyId":"gary-a-levy-o-ont-md-frcp-agaf","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Autologous Hematopoietic Stem Cell Transplant involves collecting a patient's stem cells, treating them to eliminate cancer cells, and then reinfusing them to help the body produce healthy blood cells. Used for Relapsed or refractory Hodgkin lymphoma, Relapsed or refractory non-Hodgkin lymphoma, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}